Anpocogin

DB06552InvestigationalProtein Based Therapies

Recombinant nematode anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor (TF)/factor VIIa complex with novel antithrombotic activity.

Mechanism: Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) is a potent (K(i) =10 pM), inhibitor of the factor VIIa/tissue factor (fVIIa/TF) complex that requires the prerequisite binding to zymogen or activated factor X (fX). This has been shown to attenuate the activation of coagulation and to prevent death in a primate model of sepsis caused by gram-negative bacteria.
Curator reviewed
Primary indication: Investigated for use/treatment in thrombosis (deep vein), angina, coronary artery disease, and colorectal cancer.Curator reviewed
Also known as: Recombinant nematode anticoagulant protein c2 · recombinant nematode anticoagulant protein c2 (rNAPc2) · Recombinant nematode anticoagulant protein-2 · rNAPc2

Resolves to

Compound

UNII3TTT9ZD93F

Targets

P08709F7 P13726F3 P00742F10

What you can answer from here — as of April 23, 2025

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Anpocogin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account